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Background: Adult critically ill patients often suffer from acute circu-
latory failure, necessitating use of vasopressor therapy. The aim of the
Scandinavian Society of Anaesthesiology and Intensive Care Medicine
(SSAI) task force for Acute Circulatory Failure was to present clinically
relevant, evidence-based treatment recommendations on this topic.
Methods: This guideline was developed according to standards
for trustworthy guidelines, including a systematic review of the
literature and use of the GRADE methodology for assessment of
the quality of evidence and for moving from evidence to recom-
mendations. We assessed the following subpopulations of
patients with acute circulatory failure: 1) shock in general, 2) sep-
tic shock, 3) cardiogenic shock, 4) hypovolemic shock and 5)
other types of shock, including vasodilatory shock. We assessed
patient-important outcome measures, including mortality, serious
adverse reactions and quality-of-life.
Results: For patients with shock in general and those with septic
shock, we recommend using norepinephrine rather than dopa-
mine, and we suggest using norepinephrine rather than epinephr-
ine, vasopressin analogues, and phenylephrine. For patients with
cardiogenic shock and those with hypovolemic shock, we suggest
using norepinephrine rather than dopamine, and we provide no
recommendations/suggestions of norepinephrine vs. epinephrine,
vasopressin analogues, and phenylephrine. For patients with
other types of shock, including vasodilatory shock, we suggest
using norepinephrine rather than dopamine, epinephrine, vaso-
pressin analogues, and phenylephrine.
Conclusions: We recommend using norepinephrine rather than
other vasopressors as first-line treatment for the majority of adult
critically ill patients with acute circulatory failure.
Editorial comment: what this article tells us
This guideline is focused on the choice of vasopressor in adult patients with shock. There is mod-
erate quality of evidence supporting the use of norepinephrine in patients with shock in general
and in those with septic shock. For patients with cardiogenic or hypovolemic shock, the quality
of evidence is low.
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Acute circulatory failure or shock results in
hypoperfusion and inadequate cellular oxygen
utilisation. It is a life-threatening condition that
needs prompt and appropriate treatment, since
cellular hypoxia may progress to organ failure
and death. Shock is a common condition in crit-
ical care medicine, affecting about one-third of
patients in the intensive care unit (ICU).1 His-
torically and academically, shock has been
divided into four categories based on the pre-
sumed pathophysiological mechanism: (1) hypo-
volemic shock (e.g. internal or external fluid
loss), (2) cardiogenic shock (e.g. ischaemia,
heart failure or arrhythmias), (3) obstructive
shock (e.g. pulmonary embolism, cardiac tam-
ponade, or tension pneumothorax), and (4) dis-
tributive shock (e.g. severe sepsis or
anaphylaxis from the release of inflammatory
mediators).2 In clinical practice, patients with
shock can present with a combination of these
mechanisms, and it may be more clinically rele-
vant to divide shock into categories based on
diagnostic groups.
Resuscitation of patients in shock must be
early and aggressive to prevent or limit vital
organ injury. Initial support of the failing circu-
lation generally includes intravascular volume
expansion in combination with the administra-
tion of a vasopressor.1
The Clinical Practice Committee of the Scandi-
navian Society of Anaesthesia and Intensive
Care Medicine (SSAI) initiated this guideline
on choice of first-line vasopressor in adult
patients with acute circulatory failure. The aim
was to summarise the available evidence and
provide recommendations according to current
standards for trustworthy guidelines.3–5
An electronic version of this guideline can be
accessed at www.ssai.info/guidelines/
Methods
Process
The Clinical Practice Committee of SSAI
appointed national members of the guideline
task force for Acute Circulatory Failure (the
authors of this paper). This group identified four
key interventions needing guidelines, including
fluid resuscitation,6 vasopressor therapy, inotro-
pic therapy, and cardiovascular diagnostics and
monitoring. This is the group’s second guide-
line: choice of first-line vasopressor for adult
patients with acute circulatory failure.
Clinical question
‘Which first-line vasopressor should be used for
adult critically ill patients with acute circulatory
failure’?
Population
The population of interest was adult patients (as
defined in the original trials) with acute circula-
tory failure/shock (as defined in the original tri-
als) receiving vasopressors in a high-
dependency setting in hospital, including the
emergency department, ICU, operating room,
and recovery room. The following subpopula-
tions were assessed: patients with (1) shock in
general, (2) septic shock, (3) cardiogenic shock,
(4) hypovolemic shock, and (5) other types of
shock, including vasodilatory shock.
Intervention(s)
We assessed any dose of the following vasopres-
sors: (1) dopamine, (2) vasopressin and its ana-
logues, (3) epinephrine, and (4) phenylephrine.
Comparator
The control vasopressor was norepinephrine
(any dose).
Outcome(s)
The following clinically relevant, patient-impor-
tant outcome measures7 were assessed at the
time of longest follow-up:
1. Short-term mortality (90 days or less, includ-
ing in-ICU and in-hospital mortality)
2. Long-term mortality (more than 90 days)
3. Quality-of-life as defined in the included tri-
als
4. Ischaemic events as defined in the included
trials
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5. Use of renal replacement therapy
6. Acute kidney injury as defined in the
included trials
7. Dysrhythmias as defined in the included trials
8. Length of stay (LOS) in hospital in days
We excluded systematic reviews and trials
done in children and in elective surgery, those
not reporting the predefined patient-important
outcome measures, and those not comparing
norepinephrine vs. other vasopressors, including
those comparing combinations of vasopressors
or head-to-head comparison of other vasopres-
sors than norepinephrine. Systematic reviews
and trials allowing use of adjuvant vasoconstric-
tive agents were not excluded.
Search strategy
We systematically searched PubMed (January
1966 to December 2015) and the Cochrane
Library (Issue 12, December 2015) for system-
atic reviews of randomised clinical trials (RCTs)
comparing norepinephrine with other vasopres-
sors as first-line therapy. No language restriction
was employed. If we found no relevant system-
atic review or subgroup analysis in reviews, we
searched for RCTs in PubMed, Cochrane Library
and Epistemonikos (search term (free text):
‘vasopressor*’).
Statistics and GRADE
Specific clinical questions were formulated
using the relevant patient population and/or
clinical problem (P), the intervention (I) under
scrutiny, the comparator (C), and patient-
important outcomes (O)8 – PICO questions
(Table 1).
Mantel-Haenszel statistics and random effects
models were used to generate summary
estimates (meta-analyses) if we found no
updated meta-analyses (Review Manager Ver-
sion 5.3, The Cochrane Collaboration, London,
England).
We used the Grading of Recommendations
Assessment, Development and Evaluation
(GRADE) system for formulating clinical
questions, assessing the quality of evidence,
generating anticipated absolute effects and for
moving from evidence to recommendations.5
In brief, we downgraded the quality of evi-
dence (our confidence in the effect-estimates)
for an intervention for identified risks of bias
(including lack of blinding, or early termina-
tion of studies), inconsistency (unexplained
heterogeneity), indirectness (including other
patient populations or use of surrogate out-
comes), imprecision (wide confidence interval
around the effect estimate) or publication
bias. Accordingly, the quality of evidence was
rated from ‘high’ to ‘very low’. We used Gra-
dePro v. 3.5 to prepare summary of finding
tables with anticipated relative and absolute
effects for the outcomes, together with our confi-
dence in the effect-estimates (Material S1).
When moving from evidence to recommenda-
tions, four factors were considered and inte-
grated: benefits and harms, quality of evidence,
values and preferences (of patients or their prox-
ies) and cost considerations. GRADE classifies
recommendations as ‘strong’ when virtually all
informed patients would choose the recom-
mended management strategy. ‘Weak’ recom-
mendations apply when fully informed patients
would choose different management strategies,
and reflects a close call between benefits and
harms, uncertainty regarding treatment effects,
questionable cost-effectiveness, or variability in
values and preferences.5,9 The group agreed
upon all the recommendations in this guideline.
Strong recommendations were given the word-
ing ‘we recommend’, and weak recommenda-
tions ‘we suggest’.
We followed the standards for trustworthy
guidelines through use of the GRADE system,
management of intellectual and financial con-
flicts of interest on a recommendation per rec-
ommendation basis (Material S2), a peer review
process, and a plan for updating of recommen-
dations. We did not include patient representa-
tives in the guideline process.
Results
The results and recommendations based on the
PICOs are presented below, in Table 2, and in
the summary of finding tables given in the
Material S1.
Acta Anaesthesiologica Scandinavica 60 (2016) 1347–1366
ª 2016 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation 1349
VASOPRESSORS IN ACUTE CIRCULATORY FAILURE
A. Norepinephrine vs. other vasopressors in
patients with shock in general
1. We recommend that norepinephrine is
used as first-line vasopressor for patients with
shock in general rather than dopamine
(strong recommendation, moderate quality of
evidence).
A Cochrane systematic review and meta-ana-
lysis comprising a large RCT from 2010 compar-
ing norepinephrine vs. dopamine in the
treatment of shock (the SOAP II trial) found
increased risk of dysrhythmias in patients trea-
ted with dopamine (Fig. 1, Table S1A).10,11 No
difference in short-term mortality, long-term
mortality, ischaemic events, or hospital LOS
was found (Fig. 1, Table S1A). Quality-of-life,
RRT (dichotomous) and AKI were not assessed
in the SOAP II trial.
The quality of evidence was downgraded due
to imprecision.
2. We suggest that norepinephrine is used as
first-line vasopressor for patients with shock
in general rather than epinephrine (weak rec-
ommendation, low quality of evidence).
A small RCT from 2008 comparing nore-
pinephrine and epinephrine in the treatment of
shock in general found no difference in short-
term mortality (Fig. 1, Table S1B).12 No other
outcome measures of interest have been
assessed. We believe the potential harm
associated with systematic epinephrine treat-
ment in patients with shock has been inade-
quately assessed, which is why we suggest
using norepinephrine.
Of note, this does not preclude the use of epi-
nephrine targeting any underlying condition or
co-existing disease in which epinephrine is
indicated, including anaphylactic shock.
The quality of evidence was downgraded due
to imprecision and risk of bias.
3. We suggest that norepinephrine is used as
first-line vasopressor for patients with shock
in general rather than vasopressin analogues
(weak recommendation, very low quality of
evidence).
No systematic reviews or RCTs reporting
patient-important outcome measures have com-
pared use of norepinephrine with vasopressin
analogues in patients with shock in general
(Table S1C). We believe the potential harm
associated with systematic vasopressin analogue
treatment in patients with shock has been inad-
equately assessed, which is why we – in accor-
dance with patients with septic shock – suggest
using norepinephrine.
Of note, this does not preclude the use of
vasopressin analogues targeting any underlying
condition or co-existing disease in which vaso-
pressin analogues are indicated, including dia-
betes insipidus, coagulopathy, and variceal
bleeding.
The quality of evidence was downgraded due
to imprecision, risk of bias, and indirectness.
Table 1 Clinical research questions and PICO questions used to assess evidence relevant to this guideline statement.
Clinical question
PICO Question
Population (P) Intervention (I) Comparator (C) Outcomes (O)
Should norepinephrine
or other vasopressors
be used as first-line
treatment for adult
patients with acute
circulatory failure?
Adult patients with acute
circulatory failure divided
into the following subgroups:
1. Shock in general
2. Septic shock
3. Cardiogenic shock
4. Hypovolemic shock
5. Other types of shock,
including vasodilatory shock
1. Dopamine
2. Epinephrine
3. Vasopressin analogues
4. Phenylephrine
Norepinephrine 1. Short-term mortality
2. Long-term mortality
3. Quality-of-life
4. Ischaemic events
5. Renal replacement therapy
6. Acute kidney injury
7. Dysrhythmias
8. Length of hospital stay
Acta Anaesthesiologica Scandinavica 60 (2016) 1347–1366
1350 ª 2016 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation
M. H. MØLLER ET AL.
Table 2 Key recommendations and quality of evidence.
Recommendation
Strength
of the
recommendation Benefits and harms
Quality of evidence Reason
(s) for downgrading Comments
Vasopressor treatment of patients with shock in general
1. We recommend
using
norepinephrine
rather than
dopamine
Strong No difference in short-term
mortality, long-term
mortality, ischaemic events
or hospital LOS. Increased
risk of dysrhythmias in
patients treated with
dopamine
Moderate due to imprecision
2. We suggest using
norepinephrine
rather than
epinephrine
Weak No difference in short-term
mortality. The potential harm
associated with use of
epinephrine has been
inadequately assessed
Low due to imprecision and
risk of bias
3. We suggest using
norepinephrine
rather than
vasopressin
analogues
Weak The potential harm associated
with use of vasopressin
analogues has been
inadequately assessed
Very low due to imprecision,
risk of bias, and
indirectness
No data available for this
population; data
extrapolated from patients
with septic shock
4. We suggest using
norepinephrine
rather than
phenylephrine
Weak The potential harm associated
with use of phenylephrine
has been inadequately
assessed
Very low due to imprecision,
risk of bias, and
indirectness
No data available for this
population; data
extrapolated from patients
with septic shock
Vasopressor treatment of patients with septic shock
1. We recommend
using
norepinephrine
rather than
dopamine
Strong Increased risk of dysrhythmias
and short-term mortality in
patients treated with
dopamine
Moderate due to imprecision
2. We suggest using
norepinephrine
rather than
epinephrine
Weak No difference in short-term
mortality. The potential harm
associated with use of
epinephrine has been
inadequately assessed
Low due to imprecision and
risk of bias
3. We suggest using
norepinephrine
rather than
vasopressin
analogues
Weak No difference in short-term
mortality, ischaemic events,
dysrhythmias or use of renal
replacement therapy. The
potential harm associated
with use of vasopressin
analogues has been
inadequately assessed
Low due to imprecision and
risk of bias
4. We suggest using
norepinephrine
rather than
epinephrine
Weak No difference in short-term
mortality. The potential harm
associated with use of
phenylephrine has been
inadequately assessed
Low due to imprecision and
risk of bias
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Table 2 (Continued)
Recommendation
Strength
of the
recommendation Benefits and harms
Quality of evidence Reason
(s) for downgrading Comments
Vasopressor treatment of patients with cardiogenic shock
1. We suggest using
norepinephrine
rather than
dopamine
Weak Possible increased risk of short-
term mortality. The harm
associated with dopamine
treatment in patients with
shock in general and those
with septic shock, cautions
use in other subgroups,
including patients with
cardiogenic shock
Low due to imprecision and
risk of bias
Limited data available
2. Norepinephrine vs.
epinephrine
None No data available; no
relevant populations to
extrapolate data from
3. Norepinephrine vs.
vasopressin
analogues
None No data available; no
relevant populations to
extrapolate data from
4. Norepinephrine vs.
phenylephrine
None No data available; no
relevant populations to
extrapolate data from
Vasopressor treatment of patients with hypovolemic shock
1. We suggest using
norepinephrine
rather than
dopamine
Weak No difference in short-term
mortality. The harm
associated with dopamine
treatment in patients with
shock in general and those
with septic shock, cautions
use in other subgroups,
including patients with
hypovolemic shock
Low due to imprecision and
risk of bias
Limited data available
2. Norepinephrine vs.
epinephrine
None No data available; no
relevant populations to
extrapolate data from
3. Norepinephrine vs.
vasopressin
analogues
None No data available; no
relevant populations to
extrapolate data from
4. Norepinephrine vs.
phenylephrine
None No data available; no
relevant populations to
extrapolate data from
Vasopressor treatment of patients with other types of shock, including vasodilatory shock
1. Norepinephrine vs.
dopamine
Weak The harm associated with
dopamine treatment in
patients with shock in
general and those with septic
shock, cautions use in other
subgroups, including patients
with other types of shock,
including vasodilatory shock
Low due to imprecision, and
indirectness
No data available for this
population; data
extrapolated from patients
with septic shock
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Table 2 (Continued)
Recommendation
Strength
of the
recommendation Benefits and harms
Quality of evidence Reason
(s) for downgrading Comments
2. We suggest using
norepinephrine
rather than
epinephrine
Weak No difference in short-term
mortality. The potential harm
associated with use of
epinephrine has been
inadequately assessed
Low due to imprecision and
risk of bias
Limited data available
3. We suggest using
norepinephrine
rather than
vasopressin
analogues
Weak No difference in short-term
mortality, ischaemic events
or renal replacement
therapy. The potential harm
associated with use of
vasopressin analogues has
been inadequately assessed
Low due to imprecision and
risk of bias
Limited data available
4. Norepinephrine vs.
phenylephrine
Weak The potential harm associated
with use of phenylephrine
has been inadequately
assessed
Very low due to imprecision,
risk of bias, and
indirectness
No data available for this
population; data
extrapolated from patients
with septic shock
4. We suggest that norepinephrine is used as
first-line vasopressor for patients with shock in
general rather than phenylephrine (weak rec-
ommendation, very low quality of evidence).
No systematic reviews or RCTs reporting
patient-important outcome measures have com-
pared use of norepinephrine with phenyle-
phrine in patients with shock in general
(Table S1D). We believe the potential harm
associated with systematic phenylephrine treat-
ment in patients with shock has been inade-
quately assessed, which is why we – in
accordance with patients with septic shock –
suggest using norepinephrine.
The quality of evidence was downgraded due
to imprecision, risk of bias, and indirectness.
B. Norepinephrine vs. other vasopressors in
patients with septic shock
1. We recommend that norepinephrine is used
as first-line vasopressor for patients with septic
shock rather than dopamine (strong recom-
mendation, moderate quality of evidence).
A 2012 systematic review comprising six RCTs
comparing use of norepinephrine vs. dopamine
in patients with septic shock13 showed increased
risk of mortality and dysrhythmias with dopa-
mine as compared to norepinephrine (Fig. 2,
Table S2A). Notable is the weight in the meta-
analysis of a subgroup from a large RCT (the
SOAP II trial10). No difference in hospital LOS
was found (Fig. 2, Table S2A). No other out-
come measures of interest have been assessed.
Of note, another recently published systematic
review by Avni et al.14 was considered but
excluded, as a result of methodological limita-
tions, including no published/registered proto-
col, inclusion of several high risk of bias trials,
no continuity correction in the no event trials
(sensitivity analysis), and no assessment of the
risk of random errors.15
The quality of evidence was downgraded due
to imprecision.
2. We suggest that norepinephrine is used as
first-line vasopressor for patients with septic
shock rather than epinephrine (weak recom-
mendation, low quality of evidence).
A small RCT from 2008 comparing nore-
pinephrine vs. epinephrine in the treatment of
shock in general, including a subgroup of
patients with septic shock, found no difference
in short-term mortality (Fig. 2, Table S2B).12 No
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A Short-term all-cause mortality
B Ischemic events
Fig. 1. Forest plot of (A) short-term all-cause mortality, (B) Ischemic events, (C) dysrhythmias, and (D) hospital length of stay in randomised trials
of norepinephrine (NE) vs. other vasopressors for patients with shock in general. Size of squares for risk ratio reflects weight of trial in pooled
analyses. Horizontal bars represent 95% confidence intervals.
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other outcome measures of interest have been
assessed. We believe the potential harm associ-
ated with systematic epinephrine treatment in
patients with septic shock has been inade-
quately assessed, which is why we suggest
using norepinephrine.
C Dysrhythmias
D Hospital length of stay
Fig. 1. Continued
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Of note, this does not preclude the use of epi-
nephrine targeting any underlying condition or
co-existing disease in which epinephrine is
indicated, including anaphylactic shock.
The quality of evidence was downgraded due
to imprecision and risk of bias.
3. We suggest that norepinephrine is used as
first-line vasopressor for patients with septic
shock rather than vasopressin analogues
(weak recommendation, low quality of evi-
dence).
In an updated meta-analysis comprising five
trials16–20, we found no difference in short-term
mortality, ischaemic events, dysrhythmias, or
use of renal replacement therapy in patients
with septic shock treated with norepinephrine
vs. vasopressin analogues (Fig. 2, Table S2C).
None of the other outcome measures of interest
have been assessed. We believe the potential
harm associated with systematic vasopressin
treatment in patients with septic shock has been
inadequately assessed, which is why we suggest
using norepinephrine.
Short-term all-cause mortalityA
Fig. 2. Forest plot of (A) short-term all-cause mortality, (B) ischaemic events, (C) renal replacement therapy, (D) dysrhythmias, and (E) hospital
length of stay in randomised trials of norepinephrine (NE) vs. other vasopressors for patients with septic shock. Size of squares for risk ratio
reflects weight of trial in pooled analyses. Horizontal bars represent 95% confidence intervals.
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Ischemic eventsB
C Renal replacement therapy
Fig. 2. Continued
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Hospital length of stayE
DysrhythmiasD
Fig. 2. Continued
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Of note, this does not preclude the use of
vasopressin analogues targeting any underlying
condition or co-existing disease in which vaso-
pressin analogues are indicated, including dia-
betes insipidus, coagulopathy, and variceal
bleeding.
The quality of evidence was downgraded due
to imprecision and risk of bias.
4. We suggest that norepinephrine is used as
first-line vasopressor for patients with septic
shock rather than phenylephrine (weak rec-
ommendation, low quality of evidence).
In a small RCT,21 no difference in short-term
mortality between norepinephrine vs. phenyle-
phrine was found (Fig. 2, Table S2D). None of
the other outcome measures of interest have
been assessed. We believe the potential harm
associated with systematic phenylephrine treat-
ment in patients with shock has been inade-
quately assessed, which is why we suggest
using norepinephrine.
The quality of evidence was downgraded due
to imprecision and risk of bias.
C. Norepinephrine vs. other vasopressors in
patients with cardiogenic shock
1. We suggest that norepinephrine is used as
first-line vasopressor for patients with cardio-
genic shock rather than dopamine (weak rec-
ommendation, low quality of evidence).
In a predefined subgroup of patients with car-
diogenic shock included in the SOAP II trial
(norepinephrine vs. dopamine in patients with
shock in general),10 no difference in the overall
effect of treatment between the three subgroups
assessed was reported (P = 0.87 for interaction).
However, the rate of death at 28 days was sig-
nificantly higher among patients with cardio-
genic shock who were treated with dopamine
than among those treated with norepinephrine
(Table S3A).10 No other outcome measures of
interest have been assessed. We believe the
potentially increased risk of mortality, and the
harm associated with dopamine treatment in
patients with shock in general (dysrhythmias),
cautions use of dopamine in patients with car-
diogenic shock, which is why we suggest using
norepinephrine.
Importantly, inotropes – and not vasopres-
sors – are considered the main therapy in
patients with cardiogenic shock. Excessive
dose dependent vasoconstriction may affect
cardiac output adversely. Use of inotropes in
adult patients with acute circulatory failure
will be covered in an upcoming SSAI clinical
practice guideline.
The quality of evidence was downgraded due
to risk of bias and imprecision.
2,3,4. Norepinephrine vs. epinephrine/vaso-
pressin analogues/phenylephrine for patients
with cardiogenic shock: no recommendation/
suggestion.
We could not identify any systematic reviews
or RCTs comparing norepinephrine vs. epi-
nephrine, vasopressin, or phenylephrine in
patients with cardiogenic shock. We refrain
from giving any recommendations or sugges-
tions on using norepinephrine or epinephrine/
vasopressin/phenylephrine in patients with car-
diogenic shock, as these patients are different
entities than patients with shock in general/sep-
tic shock. Importantly, norepinephrine has been
investigated quantitatively and qualitatively
more thoroughly than epinephrine, vasopressin
and phenylephrine. Consequently, we strongly
recommend that if clinicians prefer to use vaso-
pressors other than norepinephrine in patients
with cardiogenic shock, they do so in the con-
text of high-quality RCTs given the lack of data
on the balance between benefits and harms of
these drugs.
Importantly, inotropes – and not vasopres-
sors – are considered the main therapy in
patients with cardiogenic shock. Excessive
dose dependent vasoconstriction may affect
cardiac output adversely. Use of inotropes in
adult patients with acute circulatory failure
will be covered in an upcoming SSAI clinical
practice guideline.
Acta Anaesthesiologica Scandinavica 60 (2016) 1347–1366
ª 2016 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation 1359
VASOPRESSORS IN ACUTE CIRCULATORY FAILURE
D. Norepinephrine vs. other vasopressors in
patients with hypovolemic shock
1. We suggest that norepinephrine is used as
first-line vasopressor for patients with hypov-
olemic shock rather than dopamine (weak
recommendation, low quality of evidence).
In a predefined subgroup of patients with
hypovolemic shock in the SOAP II trial (nore-
pinephrine vs. dopamine in patients with shock
in general), no difference in short-term mortality
was reported (Table S4A)10. No other outcome
measures of interest have been assessed. We
believe the harm associated with dopamine treat-
ment in patients with shock in general (dysrhyth-
mias) cautions use in other subgroups, including
patients with hypovolemic shock, which is why
we suggest using norepinephrine.
Importantly, adequate fluid resuscitation
should be a priority in patients with hypov-
olemic shock, as excessive dose dependent vaso-
constriction may affect cardiac output adversely.
The quality of evidence was downgraded due
to imprecision and risk of bias.
2,3,4. Norepinephrine vs. epinephrine/vaso-
pressin analogues/phenylephrine for patients
with hypovolemic shock: no recommenda-
tion/suggestion.
We could not identify any systematic reviews
or RCTs comparing norepinephrine vs. epinephr-
ine, vasopressin, or phenylephrine in patients
with hypovolemic shock. We refrain from giving
any recommendations or suggestions on using
norepinephrine or epinephrine/vasopressin/
phenylephrine in patients with hypovolemic
shock, as these patients are different entities than
patients with shock in general/septic shock.
Importantly, norepinephrine has been investi-
gated quantitatively and qualitatively more thor-
oughly than epinephrine, vasopressin, and
phenylephrine. Consequently, we strongly rec-
ommend that if clinicians prefer to use vasopres-
sors other than norepinephrine in patients with
hypovolemic shock, they do so in the context of
high-quality RCTs given the lack of data on the
balance between benefits and harms of these
drugs.
Importantly, adequate fluid resuscitation
should be a priority in patients with hypov-
olemic shock, as excessive dose-dependent vaso-
constriction may affect cardiac output adversely.
E. Norepinephrine vs. other vasopressors in
patients with other types of shock, including
vasodilatory shock
1. We suggest that norepinephrine is used as
first-line vasopressor for patients with other
types of shock, including vasodilatory shock
rather than dopamine (weak recommenda-
tion, low quality of evidence).
We could not identify any systematic reviews
or RCTs comparing norepinephrine vs. dopa-
mine in patients with other types of shock,
including vasodilatory shock. We believe the
harm associated with use of dopamine in
patients with shock in general (dysrhythmias)
and septic shock (short-term mortality and dys-
rhythmias) cautions use in other subgroups,
including patients with other types of shock,
including vasodilatory shock. Consequently, we
suggest using norepinephrine.
The quality of evidence was downgraded due
to imprecision and indirectness.
2. We suggest that norepinephrine is used as
first-line vasopressor for patients with other
types of shock, including vasodilatory shock
rather than epinephrine (weak recommenda-
tion, low quality of evidence).
A small RCT from 2008 comparing nore-
pinephrine vs. epinephrine in the treatment of
shock in general, including a subgroup of
patients with other types of shock including
vasodilatory shock, found no difference in short-
term mortality (Fig. 3, Table S5B).12 No other
outcome measures of interest have been assessed.
We believe the potential harm associated with
epinephrine treatment in patients with other
types of shock, including vasodilatory shock has
been inadequately assessed, which is why we
suggest using norepinephrine.
Of note, this does not preclude the use of epi-
nephrine targeting any underlying condition or
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Short-term all-cause mortalityA
B Ischemic events 
Fig. 3. Forest plot of (A) short-term all-cause mortality, (B) ischaemic events, (C) renal replacement therapy, and (D) dysrhythmias in randomised
trials of norepinephrine (NE) vs. other vasopressors for patients with other types of shock, including vasodilatory shock. Size of squares for risk
ratio reflects weight of trial in pooled analyses. Horizontal bars represent 95% confidence intervals.
Acta Anaesthesiologica Scandinavica 60 (2016) 1347–1366
ª 2016 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation 1361
VASOPRESSORS IN ACUTE CIRCULATORY FAILURE
Renal replacement therapy C
D Dysrhythmias 
Fig. 3. Continued
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co-existing disease in which epinephrine is
indicated, including anaphylactic shock.
The quality of evidence was downgraded due
to imprecision and risk of bias.
3. We suggest that norepinephrine is used as
first-line vasopressor for patients with other
types of shock, including vasodilatory shock
rather than vasopressin analogues (weak rec-
ommendation, low level of evidence).
A systematic review comprising two RCTs
(n = 66)22,23 comparing use of norepinephrine vs.
vasopressin analogues in patients with vasodila-
tory shock, found no difference in short-term
mortality, ischaemic events, or renal replacement
therapy (Fig. 3, Table S5C).24 Of note, an
increased risk of dysrhythmias in patients treated
with norepinephrine was suggested (Fig. 3,
Table S5C). No other patient-important outcome
measures were asssessed. We believe the poten-
tial harm associated with treatment with vaso-
pressin analogues in patients with other types of
shock, including vasodilatory shock has been
inadequately assessed, which is why we suggest
using norepinephrine. Another recently pub-
lished systematic review by Polito et al.25 was
considered but excluded, as a result of method-
ological shortcomings.
Of note, this does not preclude the use of vaso-
pressin analogues targeting any underlying con-
dition or co-existing disease in which vasopressin
analogues are indicated, including diabetes insi-
pidus, coagulopathy, and variceal bleeding.
The quality of evidence was downgraded due
to imprecision and risk of bias.
4. We suggest that norepinephrine is used as
first-line vasopressor for patients with other
types of shock, including vasodilatory shock
rather than phenylephrine (weak recommen-
dation, very low level of evidence).
We could not identify any systematic reviews
or RCTs comparing norepinephrine vs. phenyle-
phrine in patients with other types of shock,
including vasodilatory shock (Table S5C). We
believe the potential harm associated with
phenylephrine treatment in patients with shock
has been inadequately assessed, which is why
we – in accordance with patients with septic
shock – suggest using norepinephrine.
The quality of evidence was downgraded due
to imprecision, risk of bias, and indirectness.
Discussion
This guideline on vasopressor therapy in adult
critically ill patients with acute circulatory fail-
ure has been prepared in accordance with
GRADE5 to inform readers about clinically rele-
vant issues based on current best evidence, and
to avoid advice based solely on expert opinion.
We were able to use existing systematic
reviews and RCTs to answer the majority of
clinical questions concerning choice of first-line
vasopressor in patients with shock in general
and in those with septic shock. However, for
patients with cardiogenic-, hypovolemic-, and
other types of shock, the quantity and quality of
evidence was very limited.
In general, the most widely studied compar-
isons were norepinephrine vs. dopamine, fol-
lowed by norepinephrine vs. vasopressin
analogues, whereas norepinephrine vs. epinephr-
ine and phenylephrine has hardly been assessed.
We propose two strong recommendations
favouring norepinephrine over dopamine in
patients with shock in general and in those
with septic shock. This was based on overall
low confidence of benefit from dopamine, and
importantly, confidence of harm of dopamine in
terms of increased risk of dysrhythmias (shock
in general/septic shock) and increased risk of
mortality (septic shock).
For patients with shock in general and those
with septic shock, we suggest using nore-
pinephrine over other vasopressors, as nore-
pinephrine is the most widely studied
vasopressor. The quantity and quality of evi-
dence on use of epinephrine, vasopressin ana-
logues, and phenylephrine is sparse, with the
eminent risk of overestimating benefit and
underestimating harm.26 Several interventions
which are common practice in the ICU have
been adopted based on the perception of
improved physiological parameters and physio-
logical reasoning, including changes in blood-
pressure, urinary output, and biomarkers (surro-
gate outcomes). Importantly, surrogate outcome
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measures overestimate intervention effects by
40–50%, compared to patient-centred outcome
measures.27 In a recently published analysis of
multicentre trials of critical care interventions,
eight interventions were shown to actually
increase mortality.28 Also, there is empirical evi-
dence that guideline recommendations based on
data from trials with lower quality have chan-
ged direction once higher quality trials have
been published.29 Therefore, it is recommended
that clinicians who consider other vasopressors
than norepinephrine should do so in the context
of RCTs. In this context, the results of the com-
pleted but currently unpublished VANISH trial
of norepinephrine vs. vasopressin in patients
with septic shock are very much awaited.30
For patients with cardiogenic shock and those
with hypovolemic shock, we suggest using
norepinephrine over dopamine. This was based
on overall low confidence of benefit from dopa-
mine, and importantly, the observed risk of
harm associated with dopamine treatment in
patients with shock in general10,11 and those
with septic shock.13 We believe this caution
concerning dopamine use can also be extended
(extrapolated) to other subgroups, including
patients with cardiogenic shock and hypov-
olemic shock. Because of no available data, we
were not able to provide recommendations/
suggestions for norepinephrine vs. epinephrine/
vasopressin analogues/phenylephrine in patients
with cardiogenic shock and hypovolemic shock.
We refrained from extrapolation from patients
with shock in general/septic shock, as patients
with cardiogenic shock and hypovolemic shock
are different entities.
For patients with other types of shock, includ-
ing vasodilatory shock, we suggest using nore-
pinephrine over dopamine, epinephrine,
vasopressin analogues, and phenylephrine, due
to the overall low confidence of benefit from
dopamine/epinephrine/vasopressin analogues/
phenylephrine, and importantly, since the
potential harm associated with treatment with
dopamine/epinephrine/vasopressin analogues/
phenylephrine has been inadequately assessed.
The strengths of the present guideline include
the application of current standards for trust-
worthy guidelines, including the GRADE
methodology,5 which support a systematic and
transparent process. The limitations include the
reliance upon existing systematic reviews for
some recommendations, including the risk of
trial heterogeneity and indirectness. Further-
more, not all of the included systematic reviews
and trials have been designed as a direct com-
parison between norepinephrine and another
vasopressor, as some trials have used adjuvant
(second-line) vasoconstrictive agents, including
vasopressin analogues in catecholamine refrac-
tory septic shock. Consequently, some of the
benefits and harms observed may partly be
caused by other adjuvant agents used and/or
induced changes in dosing of the vasopressors
assessed. Complicated cases of acute circulatory
failure, including patients with catecholamine
refractory shock may not be covered by the pre-
sent guideline. Overall, the quantity and quality
of evidence on vasopressor use in patients with
acute circulatory failure is limited, and addi-
tional high-quality trials on the preferred vaso-
pressor in these patients are needed.
Furthermore, our recommendations have been
restricted to those that can be based on findings
from randomised trials only. It is possible that
observational studies can provide some valuable
evidence to help form some recommendations,
however, this type of evidence is rare.31 Finally,
our guideline group did not include critical care
nurses or other relevant stakeholders, including
patient-groups, relatives, and representatives of
regulatory bodies and hospital owners.
In conclusion, we recommend/suggest using
norepinephrine as first-line therapy rather than
other vasopressors in patients with shock in
general and in those with septic shock. In
patients with cardiogenic-, hypovolemic, and
other types of shock, the quantity and quality of
evidence was in general low, and additional
high-quality data are needed. We suggest using
norepinephrine in these patients too, as the
potential harm associated with systematic use of
other vasopressors has been inadequately
assessed. For some clinical questions, no data
were available, and we refrained from giving
any recommendations or suggestions in these
circumstances.
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